New Therapies for Leishmaniasis

Partnership objective

This project aims to develop therapies to treat neglected diseases such as leishmaniasis.

This partnership aims to develop therapies to treat neglected diseases such as leishmaniasis. This partnership aims to develop therapies to treat neglected diseases such as leishmaniasis. Copyright Celgene

What are the health needs and challenges?

Visceral leishmaniasis is the second-largest parasitic killer in the world, with an estimated of 500,000 cases per year.

Description of partnership activities and how they address needs and challenges

This partnership aims to address patient needs that are not met with the current treatments available, while highlighting the experience and expertise of both organizations in the field of medicinal chemistry, adsorption, distribution metabolism and excretion, drug metabolism and pharmacokinetics expertise and design of in vivo proof-of-concept models. The partnership also reflects Celgene’s commitment to develop therapies to treat neglected diseases.

Partnership information

Company(ies) Celgene

Partner(s) Drugs for Neglected Diseases initiative (DNDi), London School of Hygiene and Tropical Medicine

Type of Partner(s) Academia / Hospitals, PDPs

Therapeutic Focus Neglected Tropical Diseases

Disease(s) Leishmaniasis

Program Type(s) Research & Development - Development of Treatments

Targeted Population(s) Patients in needs of treatment

Region(s) Latin America & Caribbean, South Asia, Sub-Saharan Africa

Number of Countries 6

Country(ies) Bangladesh, Brazil, Ethiopia, India, South Sudan, Sudan

Start Date 2012

More information 2015 Celgene CSR Report

Anticipated completion date Ongoing